Compare Cintas Corporation (CTAS) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Enveric Biosciences Inc — how do they compare? Cintas Corporation trades at $205.78 (market cap $81.25B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Cintas Corporation is far larger — about 13104.8× Enveric Biosciences Inc's market cap, and Cintas Corporation pays a 1.02% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| CTAS | ENVB | |
|---|---|---|
Market Cap | $81.25B | $6.20M |
Sector | Industrials | Health |
52-Week High | $225.10 | $17.40 |
52-Week Low | $163.55 | $1.27 |
Enterprise Value | $83.67B | $1.30M |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.05, up 0.45% on the day, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 EPS of $1.29, beating estimates, and revenue growth continues with a 17.75% net income margin. Recent news highlights Bank of America's upgrade to 'Buy' and a quarterly dividend announcement, reflecting confidence in its outlook.
The outlook for CTAS is positive, supported by consistent earnings beats and robust profitability, though high valuation multiples like a P/E of 41.35 pose a risk. Upside exists toward the consensus price target of $225.83, but investors should monitor competitive pressures and economic sensitivity.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
